Skip to main content

Table 4 Comparisons of decisions at the end of the trial according to the rules when K=2

From: Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome

    Subset A Subset B  
Scenarios Interaction method Go with EP go with SP (efficacy/interaction) nA go with SP (efficacy/interaction) nB False positive
Scenario 1 Millen 0.9622 0.0177 399.1692 0.0201 400.8308 0.0378
  Gail and Simon 0.9454 0.0282 400.2944 0.0264 399.7056 0.0546
Scenario 2 Millen 0.7259 0.2707 447.1501 0.0034 352.8499 0.0034
  Gail and Simon 0.7928 0.1934 446.8688 0.0138 353.1312 0.0138
Scenario 3 Millen 0.2025 0.7970 558.2047 0.0000 241.7953 0.0000
  Gail and Simon 0.5834 0.4080 507.3405 0.0086 292.6595 0.0086
Scenario 4 Millen 0.0067 0.9933 655.0378 0.0000 144.9622 0.0000
  Gail and Simon 0.2894 0.7106 601.0114 0.0000 198.9886 0.0000
  1. The total sample size is set at n= 800, with π=0.5 and qB=qA=0.5.
  2. *EP: entire population;
  3. *SP: subpopulation (efficacy/interaction) due to the detection of interaction with efficacy in subset k;
  4. nAand nBare the mean sample size in each subset at the end of the study